Steven Orlov1, David Z I Cherney2, Rodica Pop-Busui3, Leif E Lovblom1, Linda H Ficociello4, Adam M Smiles4, James H Warram4, Andrzej S Krolewski4, Bruce A Perkins5. 1. Division of Endocrinology and Metabolism, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; 2. Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; 3. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Health System, University of Michigan, Ann Arbor, Michigan; and. 4. Section on Genetics and Epidemiology, Research Division, Department of Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts. 5. Division of Endocrinology and Metabolism, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; bperkins@mtsinai.on.ca.
Abstract
BACKGROUND AND OBJECTIVES: Cardiac autonomic neuropathy predicts future adverse renal outcomes in the general population. This study sought to determine its relationship with early progressive renal decline in type 1 diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A subset of participants with normoalbuminuria (n=204) or microalbuminuria (n=166) from the First Joslin Kidney Study underwent assessment for cardiac autonomic neuropathy using heart rate variability during baseline visits performed from January 1991 to April 1992. Cardiac autonomic neuropathy was defined as an R-R variation (mean circular resultant) <20. Participants also had baseline and follow-up measurement of eGFR. Early progressive renal decline was evaluated according to two definitions: early GFR loss (slope of eGFR estimated by cystatin C <-3.3%/year) and incident advanced CKD (stage ≥3, defined by eGFR [calculated by Modification of Diet in Renal Disease method] <60 ml/min per 1.73 m(2)). Association with baseline cardiac autonomic neuropathy was assessed by adjusted logistic regression and Cox proportional hazards. RESULTS: Among the 370 participants, 47 (13%) had baseline cardiac autonomic neuropathy, 51 (14%) had early GFR loss, and 68 (18%) had incident advanced CKD over a median 14-year follow-up. Early GFR loss occurred in 15 (32%) of the 47 patients with baseline autonomic neuropathy and in 32 (10%) of the 323 without baseline autonomic neuropathy (P<0.001). Baseline autonomic neuropathy was strongly associated with odds of early GFR loss (adjusted odds ratio, 4.09; 95% confidence interval, 1.65 to 10.12; P=0.002). Incident advanced CKD was observed in 22 (47%) of those with baseline autonomic neuropathy and 46 (14%) of those without baseline autonomic neuropathy (P<0.001). Autonomic neuropathy was independently associated with incident advanced CKD (adjusted hazard ratio, 2.76; 95% confidence interval, 1.44 to 5.30; P=0.002). CONCLUSIONS: Cardiac autonomic neuropathy was a strong independent predictor of the long-term risk of early progressive renal decline in type 1 diabetes. Future research should explore the mechanisms by which autonomic neuropathy may be associated with renal function loss.
BACKGROUND AND OBJECTIVES:Cardiac autonomic neuropathy predicts future adverse renal outcomes in the general population. This study sought to determine its relationship with early progressive renal decline in type 1 diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A subset of participants with normoalbuminuria (n=204) or microalbuminuria (n=166) from the First Joslin Kidney Study underwent assessment for cardiac autonomic neuropathy using heart rate variability during baseline visits performed from January 1991 to April 1992. Cardiac autonomic neuropathy was defined as an R-R variation (mean circular resultant) <20. Participants also had baseline and follow-up measurement of eGFR. Early progressive renal decline was evaluated according to two definitions: early GFR loss (slope of eGFR estimated by cystatin C <-3.3%/year) and incident advanced CKD (stage ≥3, defined by eGFR [calculated by Modification of Diet in Renal Disease method] <60 ml/min per 1.73 m(2)). Association with baseline cardiac autonomic neuropathy was assessed by adjusted logistic regression and Cox proportional hazards. RESULTS: Among the 370 participants, 47 (13%) had baseline cardiac autonomic neuropathy, 51 (14%) had early GFR loss, and 68 (18%) had incident advanced CKD over a median 14-year follow-up. Early GFR loss occurred in 15 (32%) of the 47 patients with baseline autonomic neuropathy and in 32 (10%) of the 323 without baseline autonomic neuropathy (P<0.001). Baseline autonomic neuropathy was strongly associated with odds of early GFR loss (adjusted odds ratio, 4.09; 95% confidence interval, 1.65 to 10.12; P=0.002). Incident advanced CKD was observed in 22 (47%) of those with baseline autonomic neuropathy and 46 (14%) of those without baseline autonomic neuropathy (P<0.001). Autonomic neuropathy was independently associated with incident advanced CKD (adjusted hazard ratio, 2.76; 95% confidence interval, 1.44 to 5.30; P=0.002). CONCLUSIONS:Cardiac autonomic neuropathy was a strong independent predictor of the long-term risk of early progressive renal decline in type 1 diabetes. Future research should explore the mechanisms by which autonomic neuropathy may be associated with renal function loss.
Authors: Tomohito Gohda; Monika A Niewczas; Linda H Ficociello; William H Walker; Jan Skupien; Florencia Rosetti; Xavier Cullere; Amanda C Johnson; Gordon Crabtree; Adam M Smiles; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Ian H de Boer; Tessa C Rue; Yoshio N Hall; Patrick J Heagerty; Noel S Weiss; Jonathan Himmelfarb Journal: JAMA Date: 2011-06-22 Impact factor: 56.272
Authors: Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss Journal: N Engl J Med Date: 2014-04-17 Impact factor: 91.245
Authors: Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Andrzej S Krolewski; Monika A Niewczas; Jan Skupien; Tomhito Gohda; Adam Smiles; Jon H Eckfeldt; Alessandro Doria; James H Warram Journal: Diabetes Care Date: 2013-08-12 Impact factor: 19.112
Authors: Hiroki Kobayashi; Helen C Looker; Eiichiro Satake; Pierre Jean Saulnier; Zaipul I Md Dom; Kristina O'Neil; Katsuhito Ihara; Bozena Krolewski; Andrzej T Galecki; Monika A Niewczas; Jonathan M Wilson; Alessandro Doria; Kevin L Duffin; Robert G Nelson; Andrzej S Krolewski Journal: Kidney Int Date: 2022-05-23 Impact factor: 18.998
Authors: Kevin M Wheelock; Mamta Jaiswal; Catherine L Martin; Gudeta D Fufaa; E Jennifer Weil; Kevin V Lemley; Berne Yee; Eva Feldman; Frank C Brosius; William C Knowler; Robert G Nelson; Rodica Pop-Busui Journal: J Diabetes Complications Date: 2016-03-11 Impact factor: 2.852
Authors: Mamta Jaiswal; Jasmin Divers; Elaine M Urbina; Dana Dabelea; Ronny A Bell; David J Pettitt; Giuseppina Imperatore; Catherine Pihoker; Lawrence M Dolan; Angela D Liese; Santica Marcovina; Barbara Linder; Eva L Feldman; Rodica Pop-Busui Journal: Pediatr Diabetes Date: 2018-01-02 Impact factor: 4.866
Authors: Christian S Hansen; Tommi Suvitaival; Simone Theilade; Ismo Mattila; Maria Lajer; Kajetan Trošt; Linda Ahonen; Tine W Hansen; Cristina Legido-Quigley; Peter Rossing; Tarunveer S Ahluwalia Journal: Front Endocrinol (Lausanne) Date: 2022-04-14 Impact factor: 6.055